Aurinia Presents Safety and Efficacy Profile of LUPKYNIS for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024 (Businesswire) - Jun 6, 2024 - P2 | N=265 | AURA-LV (NCT02141672) | P3 | N=358 | AURORA (NCT03021499) | Sponsor: Aurinia Pharmaceuticals Inc. | "A propensity analysis comparing the pooled AURA-LV and AURORA 1 studies to the Aspreva Lupus Management Study (ALMS) suggested that a triple immunosuppressive therapy regimen of LUPKYNIS plus lower-dose MMF and low-dose steroids (≤2 g/day) resulted in earlier and greater reductions in proteinuria...Safety and efficacy outcomes for propensity-matched patients with active LN from ALMS and AURA-LV/AURORA 1 were assessed at three and six months. Patients who received the LUPKYNIS-based regimen showed >50% reduction in steroid exposure at six months and more frequently achieved a urine protein creatinine ratio (UPCR) of <0.5 mg/mg in a faster median time as compared to the high-dose two drug regimen."
Retrospective data • Lupus Nephritis
|